登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JIPH，6月22日，Prevalence and predictive value of hypocalcemia in severe COVID-19 patients》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-23

  • Prevalence and predictive value of hypocalcemia in severe COVID-19 patients

    Author links open overlay panelJingmeiLiuPingHanJingwenWuJinGongDeanTian

    Show more

    https://doi.org/10.1016/j.jiph.2020.05.029

    Abstract

    Background

    The aim of this study was to investigate the performance and predictive value of hypocalcemia in severe COVID-19 patients.

    Methods

    We retrospectively investigated the clinical and laboratory characteristics of severe COVID-19 patients. 107 patients were divided into hypocalcemia group and normal serum calcium group. The clinical and laboratory data were compared between two groups. The discriminative power of hypocalcemia regarding poor outcome were evaluated by receiver operating curves (ROC) analyze.

  • 原文来源：https://www.sciencedirect.com/science/article/pii/S1876034120305323
11浏览量
原文链接
相关报告

  • 《6月22日_低钙血症在重症COVID-19患者中的表现及预测价值》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-23
    • 信息名称：低钙血症在重症COVID-19患者中的表现及预测价值 1.时间：2020年6月22日 2.机构或团队：华中科技大学同济医学院同济医院 3.事件概要： 华中科技大学同济医学院同济医院在Journal of Infection and Public Health发表论文“Prevalence and predictive value of hypocalcemia in severe COVID-19 patients”，该文章旨在探讨低钙血症在重症COVID-19患者中的表现及预测价值。 文章回顾性调查了COVID-19重症患者的临床和实验室特征，将107例患者分为低钙组和正常血钙组。通过受试者工作曲线（ROC）分析评估低钙血症对不良结果的鉴别能力。低钙组白细胞、C反应蛋白（CRP）、降钙素原（PCT）、白介素6（IL-6）和D-二聚体水平较高，而淋巴细胞和白蛋白（ALB）水平较低，在性别、年龄、体征和症状、共病和其他实验室指标上无显著差异。血清钙水平与白细胞、CRP、PCT、IL-6、D-二聚体呈负相关，与淋巴细胞、白蛋白呈正相关。低钙血症患者的预后较差，预测预后的ROC曲线下面积（AUC）为0.73。 4.附件： 原文链接：https://www.sciencedirect.com/science/article/pii/S1876034120305323
    59浏览量
    原文链接

  • 《ChinaXiv，3月6日，Effective Treatment of Severe COVID-19 Patients with Tocilizumab》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-07
    • Effective Treatment of Severe COVID-19 Patients with Tocilizumab 提交时间： 2020-03-05 作者： Xu, Xiaoling 1 ; Han, Mingfeng 2 ; Li, Tiantian 1 ; Sun, Wei 2 ; Wang, Dongsheng 1 ; Fu, Binqing 3,4 ; Zhou, Yonggang 3,4 ; Zheng, Xiaohu 3,4 ; Yang, Yun 1 ; Li, Xiuyong 2 ; Zhang, Xiaohua 2 ; Pan, Aijun 1 ; Wei, Haiming 3,4 ; 内容摘要 Background: In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China, which spread rapidly and has become a world-wide public health challenge. We aimed to assess the efficacy of tocilizumab in severe patients with Corona Virus Disease-19 (COVID-19) and seek a new therapeutic strategy. Methods: The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People’s Hospital were given tocilizumab in addition to routine therapy between February 5 and February 14, 2020. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    59浏览量
    原文链接